Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Study Overview

This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.

Study Description

A Phase 1 Study of AG-270 in the Treatment of Subjects with Advanced Solid Tumors or Lymphoma with Homozygous Deletion of MTAP

  • ClinicalTrials.gov Identifier: NCT03435250
  • Protocol Number: 18-053
  • Principal Investigator: Gerburg Wulf
  • Principal Investigator: Central PIO

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000